TW202021565A - Compounds for neuroprotection and application thereof - Google Patents

Abstract

The present invention provides use of a compound for manufacture of a medicine for enhancing mitochondrial activity of nerve cells, wherein the compound is selected from the group consisting of trans-p-coumaryl alcohol, trans-p-acetoxycinnamoyl alcohol, and chavicol β-D-glucopyranoside. The present invention also provides use of a composition for manufacture of a medicine for enhancing mitochondrial activity of nerve cells, wherein the composition includes any one of said compounds or combinations thereof. Said compound enhances mitochondrial activity of nerve cells and also inhibits reactive oxygen species generation, thereby having the potential to protect nerve cells and prevent neurodegenerative diseases.

Description

Compounds for neuroprotection and their applications

The present invention relates to the health care use of a compound, and particularly relates to the use of a compound and a composition containing the compound for the preparation of a medicine for enhancing the activity of nerve cell mitochondria.

As the global population ages, the number of patients with neurodegenerative diseases continues to increase, resulting in more and more years of impairment of the cognition, memory, and motor abilities of the elderly. According to reports, the World Health Organization predicts that neurodegenerative diseases that affect motor function will become the second cause of epidemic death in the next two decades. Therefore, the development of treatment methods for such diseases has become one of the key research projects of modern biomedicine. Since the pathogenesis of most neurodegenerative diseases is not yet clear, there is currently a lack of effective treatment of these diseases, and the available treatments are limited to symptom management and preventing disease progression.

Mitochondria are organelles in most eukaryotic cells that undergo oxidation to generate energy. Their normal functioning is very important for maintaining cell viability. Studies have pointed out that mitochondria with normal functions are necessary for neuron to complete metabolism, nerve fiber extension, synthesis and transport of neurotransmitters. Therefore, nerve cells are particularly sensitive to mitochondrial dysfunction. At present, scholars have found that there are mitochondrial morphological abnormalities and dysfunction in Alzheimer's disease (Alzheimer's disease, AD) pathological samples or animal models, indicating that disabled mitochondria may be the cause of Alzheimer's disease One. In addition, related researchers believe that other neurodegenerative diseases, including Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) And so on, may also be related to mitochondrial dysfunction. Therefore, improving mitochondrial function is regarded as a feasible strategy to protect nerves from degenerative diseases.

In view of this, it is really necessary to develop a neuroprotective composition that can effectively improve the function or activity of mitochondria and is convenient for the general public to prevent the occurrence of the aforementioned neurodegenerative diseases.

For this reason, one object of the present invention is to provide a compound for the preparation of a drug for enhancing neuronal mitochondrial activity, wherein the compound is selected from trans-p-coumarol and trans-p-acetoxycinnamon The group consisting of alcohol, and piperonol-β-D-glucoside.

In an embodiment of the present invention, the drug for enhancing neuronal mitochondrial activity contains the aforementioned compound at a concentration of at least 10 μg/mL.

Another object of the present invention is to provide a composition for the preparation of a medicament for enhancing neuronal mitochondrial activity, wherein the composition comprises a pharmaceutically acceptable carrier, and one selected from trans-p-coumarol , Trans-p-acetoxycinnamyl alcohol, piperonol-β-D-glucoside, and any combination of compounds formed by the group.

In an embodiment of the present invention, the aforementioned compound is obtained by extracting the rhizome of Alpinia galanga with water. In a preferred embodiment, the weight ratio of the water to the rhizome of the Gaoliangyue peach is in the range of 10:1 to 5:1.

In another embodiment of the present invention, the aforementioned compound is obtained by extracting the rhizome of a Gaoliangyue peach with water and then ethyl acetate.

The present invention discloses that the administration of trans-p-coumarol, trans-p-acetoxycinnamyl alcohol, or piperonol-β-D-glucoside can significantly increase neuronal mitochondrial activity and inhibit reactive oxygen species ( Reactive oxygen species (ROS) are generated, so it has the potential to protect nerve cells and prevent neurodegenerative diseases. Accordingly, the compounds or the composition containing the compounds can be used to prepare drugs for enhancing neuronal mitochondrial activity. The drug can have a dosage form of powder, granules, solution, gel, or paste, and can be administered to a body by oral means.

The following will further illustrate the implementation of the present invention in conjunction with the drawings. The following examples are used to illustrate the features and applications of the present invention, rather than to limit the scope of the present invention. Anyone familiar with the art will not depart from Within the spirit and scope of the present invention, some changes and modifications can be made. Therefore, the protection scope of the present invention shall be subject to those defined by the appended patent scope.

Figure 1 shows that after applying a water extract of Gaoliangyue peach rhizome or its water layer extract, ethyl acetate layer extract, or n-butanol layer extract to mouse brain neuroma cell line N2a, the cells contained JC -1 The relative amount of aggregates (%).

Figure 2 shows that the mouse brain neuroma cell line N2a was treated with a water extract of Gaoliangyue peach rhizome or its water layer extract, ethyl acetate layer extract, or n-butanol layer extract, and then hydrogen peroxide After stimulation, the relative content of reactive oxygen species in the cell.

Figure 3 shows the relative amount (%) of JC-1 aggregates in the mouse brain neuroma cell line N2a after compound 1, 2, 3 or 4 was administered.

Figure 4 shows the relative content of reactive oxygen species in the mouse brain neuroma cell line N2a after compound 1, 2, 3 or 4 was applied and then stimulated with hydrogen peroxide.

The present invention provides the use of a compound for the preparation of a medicament for enhancing neuronal mitochondrial activity, wherein the compound is selected from the group consisting of trans-p-coumarol, trans-p-acetoxycinnamyl alcohol, and piperonol-β -D-glucoside group consisting of. The present invention also provides a use of a composition containing any of the foregoing compounds or any combination thereof for preparing a medicine for enhancing neuronal mitochondrial activity. The following examples show that administering any of the foregoing compounds or a composition containing these compounds to nerve cells can increase mitochondrial activity and inhibit the production of reactive oxygen species.

definition

The numerical values used herein are approximate values, and all experimental data are expressed in the range of 20%, preferably in the range of 10%, and most preferably in the range of 5%.

The so-called "mitochondrial activity" in this article refers to the effectiveness of mitochondrial operations, including the efficiency of energy production and material metabolism. The assessment of mitochondrial activity can be accomplished according to the biochemical, molecular biology and cytological techniques known in the technical field of the present invention, such as the measurement of mitochondrial membrane potential described herein. The terms "mitochondrial activity" and "mitochondrial function" are interchangeable.

The "pharmaceutically acceptable carrier" used herein refers to a pharmaceutically acceptable solvent, or an excipient or stabilizer in the form of a solid or solution. The pharmaceutically acceptable carrier is non-toxic to the recipient at the dose and concentration used, and may include buffers, such as phosphate, citrate and other organic acids; antioxidants, such as ascorbic acid; amino acids, such as glycine ; Polypeptides, such as gelatin; monosaccharides, disaccharides, polysaccharides, and other carbohydrates, such as glucose, sucrose, and trehalose.

Materials and Methods material

DMEM medium (Gibco Dulbecco's modified Eagle's medium), Gibco fetal bovine serum (FBS), antibiotics (Gibco Antibiotic-Antimycotic), sodium bicarbonate, and phosphate buffered saline were purchased from Thermo Fisher Scientific. PBS). Purchase 2,7-dichloro-dihydro-fluorescein diacetate (DCFH-DA; product code SI-D6883) from Sigma, and dissolve it in dimethyl sulfide before use. sulfoxide, DMSO) to prepare a 5mg/mL DCFH-DA solution.

The solvent purchased from Taiwan Merck, comprising n-hexane (n -hexane), ethyl acetate (ethyl acetate), acetone (acetone), methanol (Methanol), ethanol (Ethanol), acetonitrile (acetonitrile), chloroform - d ₁ (degree of deuteration 99.5%), methanol - d ₆ (deuterated degree 99.5%), heavy water (deuterium oxide, deuterated degree> 99.8%), and dimethyl sulfoxide _{- d 6 (dimethyl sulfoxide- d 6} , deuterium Degree of chemistry>99.9%).

Chemical analysis equipment

The compound separation system utilizes column chromatography (column chromatography) and thin layer chromatography (thin layer chromatography, TLC). The medium pressure liquid chromatography (MPLC) system is Combi Flash ^® Rf+ (Teledyne ISCO); the column is selected from Sephadex LH-20 (Amersham Biosciences), Diaion HP-20 (Mitsubishi Chemical), Merck Kieselgel 60 (40-63μm, Art. 9385), and Merck LiChroprep® RP-18 (40-63μm, Art. 0250). The high performance liquid chromatography (HPLC) system is equipped with Hitachi L-2310 series pumps, Hitachi L-2420 UV-VIS detector (detection wavelength is 200nm to 380nm), and D-2000 Elite data processing Software; the column is selected from the analytical grade Discovery® HS C ₁₈ (250×4.6mm, 5μm; SUPELCO) and Mightysil RP-18 GP 250 (250×4.6mm, 5μm; Kanto Chemical), and the semi-preparative Discovery® HS C ₁₈ (250×10.0mm, 5μm; SUPELCO) and preparative Discovery® HS C ₁₈ (250×21.0mm, 5μm; SUPELCO). Chromatography system is equipped with UV lamp UVP UVGL-25 (wavelength is 254nm and 365nm). Thin-layer chromatography sheet is coated with silicone 60 F ₂₅₄ (0.25mm; Merck) or RP-18 F _254S (0.25mm; Merck) aluminum sheet.

The chemical structure of the compound is determined by mass spectrometry (MS) and nuclear magnetic resonance spectrometry (NMR). Specifically, two-dimensional ion trap series Fourier transform mass spectrometry (Bruker amaZon SL system) and electrospray ionization series Mass spectrometry (ESI-MS/MS; Thermo Scientific Orbitrap Elite system); and use 400MHz Varian 400 FT-NMR to obtain 1D and 2D NMR spectra, with tetramethylsilane (TMS) as the internal standard.

Cell culture

The following examples use the mouse brain neuroma cell line N2a (ATCC CCL-131) purchased from the American Type Culture Collection (ATCC). N2a cells were cultured in DMEM medium under the conditions of 37°C and 5% carbon dioxide. The medium was supplemented with 10% FBS, 3.7 g/L sodium bicarbonate, and 1% antibiotics, hereinafter referred to as cell culture medium.

Mitochondrial activity analysis

In order to evaluate the mitochondrial activity of the cells, the changes in the mitochondrial membrane potential were measured by flow cytometer (Beckman Coulter Life Sciences) and the mitochondrial membrane potential detection kit (BD ^TM MitoScreen). In short, N2a cells were seeded in 6-well plates at 1×10 ⁵ cells/well, and each well contained 2 mL of cell culture medium. After culturing the cells at 37°C for 24 hours, the medium was removed, and the cells were treated with 1 mL of cell culture medium supplemented with the sample to be tested (experimental group), or cells were treated with cell culture medium only (control group). The cells of each group were cultured at 37°C for 24 hours and then analyzed for mitochondrial activity according to the following steps. According to the manufacturer's instructions, rinse the cells to be tested with PBS solution, then collect the cells into a 1.5 mL microcentrifuge tube and centrifuge (400 xg, 5 minutes). After removing the supernatant, the cells were resuspended in PBS solution and centrifuged again (400 xg, 5 minutes). Mix 100μL of JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazo-lylcarbocyanine iodide) operating solution with the precipitated cells in the dark for 15 minutes for fluorescence Mark, and wash the cells twice with washing buffer and centrifugation step (400 xg, 5 minutes). Finally, resuspend the cells in a 2% FBS-containing PBS solution, and use a flow cytometer to detect the relative amount of JC-1 aggregates indicating mitochondrial membrane potential (excitation wavelength is about 490nm, detection wavelength is about 595nm ). The greater the amount of JC-1 aggregates, the greater the potential difference in the inner mitochondrial membrane, which is regarded as the higher the mitochondrial activity.

Active oxygen species production test

The fluorescent probe DCFH-DA was used in conjunction with a flow cytometer (Beckman) to determine the content of reactive oxygen species in N2a cells after designated treatment. In short, N2a cells were seeded in 6-well culture plates at 2×10 ⁵ cells/well, and each well contained 2 mL of cell culture medium. After culturing the cells at 37°C for 24 hours, the medium was removed, and the cells were treated with 1 mL of cell culture medium supplemented with the sample to be tested (experimental group), or cells were treated with cell culture medium only (control group). Thereafter, the cells in each well were treated with 5 μg/mL DCFH-DA for 15 minutes, and then treated with 1 mM hydrogen peroxide (dissolved in PBS solution) at 37° C. for 1 hour, and then washed twice with 1 mL of PBS solution. The washed cells were reacted with 200μL trypsin in the dark for 5 minutes and then collected into a 1.5mL test tube in the dark, and centrifuged at 400 xg for 10 minutes to remove the supernatant. The remaining pellet was washed once with PBS solution, then centrifuged at 400 xg for 10 minutes and the supernatant was removed. Finally, the cells were resuspended in 1 mL of PBS solution, and the fluorescence intensity of the cells was detected by a flow cytometer. The excitation wavelength for fluorescence detection is 450 to 490 nm, and the detection wavelength is 510 to 550 nm. Since DCFH-DA enters the cell, it will be firstly hydrolyzed to DCFH (dichlorodihydroluciferin), and then oxidized by reactive oxygen species to DCF (dichloroluciferin) that emits green fluorescence, and is treated by DCFH-DA The fluorescence intensity of the cell can reflect the content of reactive oxygen species in the cell.

Statistical Analysis

The statistically significant difference of the experimental data is determined by the student t test of Excel software.

Example 1 A compound purified from the rhizome of Gaoliangyue peach to enhance the activity of neuronal mitochondria

In order to obtain compounds that enhance the mitochondrial activity of nerve cells, a water extract of the rhizome of Gaoliangyuetao (also known as galangal) is first prepared. In short, the rhizome of Gaoliangyue peach is washed, dried, cut into pieces, and then broken into about 1 to 2 cm with a crusher. Afterwards, the water extract of the rhizome of Gaoliangyue peach can be obtained by extracting the ground material of the rhizome of Gaoliangyue peach with water as a solvent. The weight ratio of the solvent to the pulverized product ranges from 10:1 to 5:1. The extraction temperature is between 70°C and 100°C, preferably between 80°C and 90°C. The extraction time in this embodiment is 1 to 2 hours.

In order to remove the residual solids, the water extract of the rhizome of Gaoliangyue peach obtained by the above extraction step is cooled to room temperature, and then centrifuged at 2500 to 3500 rpm at 15°C to 25°C for 5 to 10 minutes to obtain a Supernatant. The supernatant can be further concentrated under reduced pressure at 45°C to 70°C to obtain a concentrated product.

Thereafter, a secondary extract rich in neuroprotective active ingredients was further separated from the water extract of the rhizome of Gaoliangyue peach. The steps are briefly described as follows. First, the water extract (5L) of the rhizome of Gaoliangyue peach was extracted three times by means of liquid-phase distribution in equal proportions of ethyl acetate and water. The obtained ethyl acetate layer extracts were combined, and then concentrated and dried under reduced pressure to obtain about 2.1 g of an ethyl acetate layer extract. The remaining aqueous layer extracts are extracted three times in a liquid phase distribution method with equal proportions of n-butanol and water. The resulting n-butanol layer extract and water layer The extracts were combined separately, and then concentrated and dried under reduced pressure to obtain about 10 g of an n-butanol layer extract and about 98 g of an aqueous layer extract.

In order to evaluate the neuroprotective effect, the mouse brain neuroma cell line N2a was treated with 10μg/mL of the above-mentioned Gaoliangyue peach rhizome water extract, water layer extract, ethyl acetate layer extract, or n-butanol layer extract Cell culture medium, or just treat the cells with cell culture medium (control group). The cells of each group were cultured at 37°C for 24 hours and then used for mitochondrial activity analysis. The fluorescent dye JC-1 in the aforementioned mitochondrial membrane potential detection kit was used to indicate the mitochondrial membrane potential. Figure 1 shows the relative amount (%) of JC-1 aggregates in Na2 cells in each of the aforementioned groups. The higher the value, the higher the average mitochondrial activity of the cells; ^* and ^{** in the} figure respectively indicate p compared to the control group <0.05 and p<0.01. According to Figure 1, compared with the control group, the water extract of the roots and stems of Gaoliangyue peach significantly increased the mitochondrial activity of N2a cells by about 38%, and among the three secondary extracts, only the ethyl acetate layer extract significantly improved Mitochondrial activity is about 188%. This result shows that the ethyl acetate layer extract of the water extract of Gaoliangyue peach rhizome contains neuroprotective active ingredients that can enhance the activity of mitochondria.

Considering that the increase in mitochondrial activity may be accompanied by an increase in the production of reactive oxygen species in the cell, further tests were performed on the mouse brain neuroma cell line N2a containing 62.5μg/mL of the aforementioned Gaoliangyue peach rhizome water extract, water layer extract, and acetic acid After the ethyl acetate layer extract or the cell culture medium of the n-butanol layer extract, the relative content of reactive oxygen species (relative to the reactive oxygen species content of the cells of the control group) under the stimulation of 1 mM hydrogen peroxide. According to Figure 2, compared with the control group cells treated with cell culture medium only, hydrogen peroxide treatment induces the production of reactive oxygen species in N2a cells, but the water extract from the roots of Gaoliangyue peach at the same time significantly reduces the N2a cells by about 35.3 % Of active oxygen species accumulate, especially only the ethyl acetate layer extract significantly inhibits the generation of about 80.5% of active oxygen species. This result indicates that the ethyl acetate layer extract of the water extract of Gaoliangyue peach rhizome can enhance the activity of mitochondria while inhibiting the increase of nerve cell oxidative stress.

Based on the results of the analysis of mitochondrial activity and the production of reactive oxygen species, potential compounds that enhance neuronal mitochondrial activity were further isolated from the aforementioned ethyl acetate layer extract. According to the bioassay guided fractionation method, using a silica gel column and an eluent mixed with n-hexane and ethyl acetate in a volume ratio of 100:1, the ethyl acetate layer extract is subjected to column chromatography. Obtain 18 divided layers (labeled F1 to F18 respectively). Afterwards, the F3 divided layer is subjected to column chromatography, and the resulting effluent is separated by a thin layer chromatography sheet to obtain 5 divided layers (labeled F3-1 to F3-5 respectively). F3-2 is divided into layers, and then a mixture of methanol and water in a volume ratio of 2:8 is used as the mobile phase for high performance liquid chromatography (HPLC), and compound 1 (about 25.3 mg) can be separated.

F2 division layer is further separated by reverse phase chromatography column RP-18 to obtain 6 division layers (respectively labeled F2-1 to F2-6). F2-4 was divided into layers and then subjected to high performance liquid chromatography with a mixture of methanol and water in a volume ratio of 2:8 as the mobile phase to separate compound 2 (about 3.0 mg) and compound 4 (about 2.5 mg).

In addition, using Sephadex LH-20 column and methanol extract to perform column chromatography on the F7 division layer, 5 division layers (respectively labeled F7-1 to F7-5) can be obtained. F7-3 is divided into layers, and then a mixture of methanol and water in a volume ratio of 3:7 is used as the mobile phase for high performance liquid chromatography, and compound 3 (about 5.3 mg) can be isolated.

The chemical structures of compounds 1, 2, 3, and 4 were determined by mass spectrometer and nuclear magnetic resonance spectrometer analysis. The names and structural formulas are shown in Table 1 below.

Example 2 Compound 1-3 enhances neuronal mitochondrial activity

This example uses mitochondrial activity analysis to test the effect of compound 1, 2, 3, or 4 (at a concentration of 10 μg/mL) on improving neuronal mitochondrial activity. The results are shown in Figure 3; * and ** in the figure respectively It means p<0.05 and p<0.01 compared to the control group. According to Fig. 3, compared with the control group N2a cells treated with cell culture medium only, the treatments of Compound 1, 2, and 3 all significantly increased the mitochondrial activity in N2a cells. Specifically, Compound 1, 2, or 3 increased mitochondrial activity by approximately 100%, 29.9%, and 39.9%, respectively. However, compound 4 has not been observed to have this improvement effect.

Example 3 Compound 1-3 inhibits the production of reactive oxygen species in nerve cells

In this example, a reactive oxygen species production test was used to test the inhibitory effect of compound 1, 2, 3, or 4 (at a concentration of 10 μg/mL) on the production of reactive oxygen species in nerve cells stimulated by hydrogen peroxide. The results are shown in Figure 4 ; * And ** in the figure indicate p<0.05 and p<0.01 respectively compared to the application of hydrogen peroxide alone. According to Figure 4, compared with N2a cells treated with 1 mM hydrogen peroxide, simultaneous administration of Compound 1, 2, or 3 significantly reduced the accumulation of reactive oxygen species in N2a cells. Specifically, compounds 1, 2, 3, and 4 reduced the relative content of active oxygen species by approximately 60.5%, 77.8%, 34.2%, and 28.5%, respectively.

In summary, the present invention discloses that the administration of trans-p-coumarol, trans-p-acetoxycinnamyl alcohol, and piperonol-β-D-glucoside can significantly increase neuronal mitochondrial activity, and Inhibit the production of reactive oxygen species, so it has the potential to protect nerve cells and prevent neurodegenerative diseases. Accordingly, the compounds or the composition containing the compounds can be used to prepare drugs for enhancing neuronal mitochondrial activity. The drug can have a dosage form of powder, granules, solution, gel, or paste, and can be administered to a body by oral means.

Claims (10)

The use of a compound for the preparation of a drug for enhancing the activity of neuronal mitochondria, wherein the compound is selected from the group consisting of trans-p-coumarol, trans-p-acetoxycinnamyl alcohol, and piperonol-β-D- The group consisting of glucoside. The use as described in item 1 of the scope of patent application, wherein the concentration of the compound is at least 10 μg/mL. The use described in item 1 of the scope of patent application, wherein the drug is administered orally. The use described in item 1 of the scope of patent application, wherein the drug has a dosage form of powder, granule, solution, gel, or paste. The use of a composition for the preparation of a medicament for enhancing neuronal mitochondrial activity, wherein the composition comprises a pharmaceutically acceptable carrier, and one selected from the group consisting of trans-p-coumarol and trans-p-acetoxy Cinnamyl alcohol, piperonol-β-D-glucoside, and any combination of these compounds. The use described in item 5 of the scope of patent application, wherein the compound is obtained by extracting the rhizome of a Gaoliangyue peach with water. For the purpose described in item 6 of the scope of the patent application, the weight ratio of the water to the rhizome of the Gaoliangyue peach is in the range of 10:1 to 5:1. The use as described in item 5 of the scope of patent application, wherein the compound is obtained by extracting the rhizome of a Gaoliangyue peach with water and then ethyl acetate. The use described in item 5 of the scope of patent application, wherein the drug is administered orally. The use as described in item 5 of the scope of patent application, wherein the drug has a dosage form of powder, granule, solution, gel, or paste.

Images